INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Core Viewpoint - INVO Fertility, Inc. has announced a private placement offering to raise approximately $4.0 million through the sale of common stock and warrants, aimed at expanding its operations in the fertility market [1][2]. Group 1: Offering Details - The company will sell 2,366,864 shares of common stock and warrants to purchase up to 4,733,728 additional shares, with a combined effective offering price of $1.69 per share [1]. - The warrants will have an exercise price of $1.69 per share, exercisable upon shareholder approval, and will expire five years from the date of such approval [1]. - The offering is expected to close on or about December 3, 2025, pending customary closing conditions [2]. Group 2: Financial Implications - Gross proceeds from the offering are estimated to be approximately $4.0 million before deducting fees and expenses related to the placement [2]. - Maxim Group LLC is acting as the sole placement agent for this offering [2]. Group 3: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell technology [5]. - The company operates two INVO Centers and one IVF clinic in the United States, offering the intravaginal culture (IVC) procedure, which is designed to provide a more natural and cost-effective alternative to traditional IVF [5]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, potentially delivering comparable results to traditional methods at a lower cost [5].